Shawn Leland, Fore Biotherapeutics interim CEO
August 23, 2023 10:30 AM EDT
Financing
Startups

Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Kyle LaHucik

Senior Reporter

Fore Bio­ther­a­peu­tics has reeled in a $75 mil­lion Se­ries D, and its CEO Matthew Ros is walk­ing off the course for “oth­er pro­fes­sion­al pur­suits,” the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times